Condition: Breast Cancer · Sponsor: iOMEDICO AG
The objective of this non-interventional study (NIS) is to evaluate prevalence of ESR1 mutation after endocrine therapy in the palliative setting, quality of life, tolerability, and safety and to describe treatment detail and adverse event (AE) management in postmenopausal women with locally advanced and/or metastatic ER+ HER2- ESR1-mutated breast cancer and second line treatment with elacestrant according to SmPC (Summary of product characteristics) in a real-world setting.
This description comes directly from the study's public registry record.
Laura Serrer · +49761152420 · eleni@iomedico.com
Always discuss trial participation with your own doctor first.
| Praxis für interdisziplinäre Onkologie & Hämatologie | Freiburg im Breisgau, Germany | Recruiting |
| St. Louise Frauen- und Kinderklinik | Paderborn, Germany | Recruiting |
| Gemeinschaftspraxis für Hämatologie und Onkologie | Ravensburg, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07563595